Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
muscarinic receptor antagonist, GSK573719,, chronic obstructive pulmonary disease,
Brief summary
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK573719 when administered via inhalation in animal models supports the potential for use as a once-daily bronchodilator for COPD
Detailed description
A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, 3-cohort parallel-group study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GSK573719 administered as single doses (750µg and 1000µg) and repeat doses over 14 days (250µg-1000µg once-daily) of GSK573719 in healthy male and female subjects
Interventions
DRUGGSK573719
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy Caucasian male subjects or healthy Caucasian female subjects of non-childbearing potential * Aged between 18-55 years * Non-smokers * Normal spirometry (FEV1 = 80% of predicted, FEV1/FVC = 70%) * A signed and dated written informed consent is obtained from the subject * The subject is capable of giving informed consent * Available to complete the study * Subject has a BMI within the range 18.0-30.0kg/m2 inclusive
Exclusion criteria
* Any clinically important abnormality identified at the screening medical assessment * A history of breathing problems * A mean QTc(B) value at screening \>450msec, the QTc(B) of all 3 screening ECGs are not within 10% of the mean, or an ECG that is not suitable for QT measurements * A history of elevated resting blood pressure or a mean blood pressure equal to or higher than 140/90 mmHg at screening * A mean heart rate outside the range 40-90 bpm at screening * History of use of tobacco products within 6 months of screening, or positive urine cotinine at screening * Subjects with a 2D6 poor metabolizer genotype (Caucasian) * The subject has donated a unit (400ml) of blood within 60 days of screening, or, intends to donate during the study * The subject is currently taking regular (or course of) medication, whether prescribed or not * The subject has taken prescription medications within the past 2 weeks prior to dosing or OTC medications within 48 hours prior to dosing * The subject has participated in a study with a new molecular entity or any other trial within a period of 3 months prior to dosing * The subject has tested positive for hepatitis C antibody, hepatitis B surface antigen or HIV * The subject has a positive pre-study drug screen * The subject has a positive pre-study alcohol screen * The subject has a suspected history of alcohol abuse within the six months previous to the screening visit * The subject is unable to use the DISKUS * The subject has a known allergy or hypersensitivity to ipratropium bromide, atropine and any of its derivatives * The subject has a known allergy or hypersensitivity to milk protein or the excipient lactose monohydrate * Subjects who might have prostatic hypertrophy, bladder outlet obstruction, or narrow angle glaucoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| General safety and tolerability endpoints: adverse events, blood pressure, heart rate, 12-lead ECG, Holter and Lead II ECG monitoring, lung function and clinical laboratory safety tests throughout the study | throughout the study |
Secondary
| Measure | Time frame |
|---|---|
| - Ambulatory blood pressure for repeat dosing - 24hr Holter monitoring for repeat dosing - Plasma and urine concentrations of GSK573719 and derived pharmacokinetic parameters | throughout the study |
Countries
Germany
Outcome results
None listed